Policies to aid the adoption of personalized medicine

Charity Nofziger; Marisa Papaluca; Andre Terzic; Scott Waldman; Markus Paulmichl

doi:10.1038/nrd4257

Policies to aid the adoption of personalized medicine

Charity Nofziger, Marisa Papaluca, Andre Terzic, Scott Waldman, Markus Paulmichl

Cardiovascular Medicine

Research output: Contribution to journal › Comment/debate › peer-review

7 Scopus citations

Original language	English (US)
Pages (from-to)	159-160
Number of pages	2
Journal	Nature Reviews Drug Discovery
Volume	13
Issue number	3
DOIs	https://doi.org/10.1038/nrd4257
State	Published - Mar 2014

ASJC Scopus subject areas

Pharmacology
Drug Discovery

Access to Document

10.1038/nrd4257

Cite this

@article{a8f7eb3bb8bf432f95e49f70a770a2cd,

title = "Policies to aid the adoption of personalized medicine",

author = "Charity Nofziger and Marisa Papaluca and Andre Terzic and Scott Waldman and Markus Paulmichl",

note = "Funding Information: Research funding. A key barrier to the development of personalized medicine has been the lack of resources to generate a critical mass of the necessary scientific data and enabling tools. In Europe, the new EU Framework Programme for Research and Development (known as Horizon 2020) will invest ~€70 billion in collaborative health research, which could enable personalized medicine approaches1. Within Horizon 2020, funding through the Framework Programmes for Research and Technological Development, the Competitiveness and Innovation Framework Programme and the European Institute of Innovation and Technology will be unified, and proposals in the area of personalized medicine are one research priority. Moreover, there are plans to extend the existing Innovative Medicines Initiative (IMI) frame-work into IMI-2, which could provide further funding for public–private partnerships in this area.",

year = "2014",

month = mar,

doi = "10.1038/nrd4257",

language = "English (US)",

volume = "13",

pages = "159--160",

journal = "Nature Reviews Drug Discovery",

issn = "1474-1776",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Policies to aid the adoption of personalized medicine

AU - Nofziger, Charity

AU - Papaluca, Marisa

AU - Terzic, Andre

AU - Waldman, Scott

AU - Paulmichl, Markus

N1 - Funding Information: Research funding. A key barrier to the development of personalized medicine has been the lack of resources to generate a critical mass of the necessary scientific data and enabling tools. In Europe, the new EU Framework Programme for Research and Development (known as Horizon 2020) will invest ~€70 billion in collaborative health research, which could enable personalized medicine approaches1. Within Horizon 2020, funding through the Framework Programmes for Research and Technological Development, the Competitiveness and Innovation Framework Programme and the European Institute of Innovation and Technology will be unified, and proposals in the area of personalized medicine are one research priority. Moreover, there are plans to extend the existing Innovative Medicines Initiative (IMI) frame-work into IMI-2, which could provide further funding for public–private partnerships in this area.

PY - 2014/3

Y1 - 2014/3

UR - http://www.scopus.com/inward/record.url?scp=84895814542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895814542&partnerID=8YFLogxK

U2 - 10.1038/nrd4257

DO - 10.1038/nrd4257

M3 - Comment/debate

C2 - 24577385

AN - SCOPUS:84895814542

SN - 1474-1776

VL - 13

SP - 159

EP - 160

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

IS - 3

ER -

Policies to aid the adoption of personalized medicine

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this